Basic Requip Information

• INN (International Nonproprietary Name): Ropinirole.
• Brand Names Available In United Kingdom: Requip is marketed in the UK and internationally in tablet strengths 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg.
• Brand Names Available In United Kingdom: Requip XL (extended‑release) is available in the EU and in markets outside the US in 2 mg, 4 mg, 6 mg, 8 mg and 12 mg strengths.
• Brand Names Available In United Kingdom: Adartrel appears in some EU markets and generic ropinirole products are widely available from multiple manufacturers.
• ATC Code: N04BC04 — N: Nervous System; 04: Anti‑Parkinson Drugs; B: Dopamine Agonists; C04: Selective Dopamine Agonists (Ropinirole).
• Forms & Dosages: Immediate‑release tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg; Extended‑release tablets 2 mg, 4 mg, 6 mg, 8 mg and 12 mg.
• Manufacturers In United Kingdom: Original developer GlaxoSmithKline and multiple generic suppliers are listed globally including Teva, Mylan, Sandoz, Accord and Sun Pharma; generics are commonly supplied to the UK market.
• Registration Status In United Kingdom: Requip and ropinirole generics are available in the UK and EU; regulatory registrations are held in European markets (EMA) and generics remain widely authorised.
• OTC / Rx Classification: Prescription only (Rx) in all markets.
• Standard Dosages Per Indication: Parkinson’s disease initial dose commonly 0.25 mg three times daily with slow weekly increases up to a maximum of 24 mg daily; Restless Legs Syndrome initial 0.25 mg once daily 1–3 hours before bedtime with an approximate maximum of 4 mg daily.
• Dosage Adjustments: Not established for children; elderly require careful monitoring and slower titration; use with caution in liver impairment; dose adjustments may be necessary in severe renal impairment.
• Storage And Transport Guidelines: Store at 20–25°C with permitted excursions 15–30°C; keep in original, tightly closed container and protect from light and moisture.
• Absolute Contraindication: Hypersensitivity to ropinirole or excipients.

Key Findings From Recent Trials

Major 2022–2025 Studies

What Does The Latest Research Say About Requip And Ropinirole?

Large randomised controlled trials and pooled meta‑analyses from 2022–2025 continued to compare ropinirole with placebo and other non‑ergot dopamine agonists.

Several ER formulation trials tested once‑daily extended‑release ropinirole against its immediate‑release counterpart for both Parkinson’s disease and restless legs syndrome.

Trials emphasised adherence, peak‑trough adverse events and behavioural safety screening during follow‑up.

Requip XL and generic extended‑release ropinirole formulations were included in many multicentre studies across Europe.

Main Outcomes

Did Patients Notice A Difference In Symptoms?

Ropinirole showed consistent symptomatic efficacy versus placebo for motor symptoms in Parkinson’s disease and for sensory motor symptoms in RLS.

Effect sizes were broadly comparable with other non‑ergot agonists such as pramipexole in head‑to‑head and pooled analyses.

Extended‑release formulations demonstrated improved adherence and fewer peak‑related adverse events when compared with immediate‑release dosing schedules.

Clinical endpoints commonly improved faster with adequate titration, with many patients reporting benefit within days to weeks depending on dose escalation.

Safety Observations

What Safety Signals Emerged In Recent Trials?

Trials since 2022 tightened surveillance for impulse control disorders, sudden sleep episodes and orthostatic hypotension.

Impulse control disorders such as pathological gambling and hypersexuality were detected more reliably because protocols included standardised behavioural screening tools.

Post‑marketing data reinforced that nausea and dizziness remain common but that slow titration reduces discontinuation.

ER dosing reduced peak‑related nausea and orthostatic symptoms in a number of studies, supporting the clinical role of Requip XL and generic ER ropinirole for suitable patients.

Clinical Mechanism Of Action

Layman’s Explanation

How Does Requip Help With Parkinson’s And RLS?

Ropinirole acts like dopamine in the brain to ease tremor, slowness and stiffness in Parkinson’s disease.

It also calms the unpleasant sensations and urge to move in restless legs syndrome when taken in the evening.

Patients often describe it as smoothing movement and reducing night‑time leg discomfort.

Scientific Breakdown

What Happens At A Receptor Level?

Ropinirole is a selective dopamine receptor agonist assigned ATC code N04BC04.

It binds primarily to D2‑family receptors, especially D2 and D3 subtypes, in the striatum to modulate basal ganglia circuits.

This restores dopaminergic signalling and reduces motor symptoms in Parkinson’s disease.

Immediate‑release tablets are given multiple times daily while extended‑release tablets (Requip XL and generics) allow once‑daily dosing with smoother plasma levels.

Hepatic metabolism predominates so dose caution is advised in significant liver impairment and severe hepatic impairment is usually avoided.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

What Is Ropinirole Licensed For In The UK?

Ropinirole is licensed for Parkinson’s disease and restless legs syndrome in European and UK markets.

Requip and Requip XL — plus multiple generics and branded generics such as Adartrel — are supplied in the UK and EU.

Immediate‑release tablets are typically used TID for Parkinson’s and low evening doses are used for RLS.

Notable Off‑Label Trends

How Do Clinicians Use Ropinirole Outside The Licence?

Neurology units will sometimes use ropinirole for dopaminergic‑responsive dystonia or as an alternative agonist when pramipexole is poorly tolerated.

Clinicians also apply ropinirole in RLS augmentation strategies and favour ER formulations in elderly patients to aid adherence.

Generics are widely used across formularies, and clinicians must align prescribing with local guidelines and counselling requirements for behavioural and sleep risks.

Dosage Strategy

General Dosing

What Are The Principles When Starting Ropinirole?

Start low and titrate slowly to reduce nausea, dizziness and sudden sleep risk.

Monitor frequently while increasing the dose and adjust according to clinical response and tolerability.

Immediate‑release tablets are given multiple times daily for Parkinson’s while ER tablets support once‑daily dosing.

Condition‑Specific Dosing

How Much Should Be Given For Each Condition?

For Parkinson’s disease, a common starting regimen is 0.25 mg three times daily with gradual weekly increases to effect, up to a maximum of 24 mg daily as tolerated.

For Restless Legs Syndrome, initiation at 0.25 mg once daily 1–3 hours before bedtime is typical, with a usual upper limit around 4 mg daily.

Elderly patients need slower titration and patients with severe hepatic impairment may require avoidance or specialist review.

Missed doses should be taken when remembered unless close to the next dose; do not double doses.

Overdose can cause hallucinations, agitation, vomiting and abnormal movements — seek emergency care immediately.

Safety Protocols

Contraindications

Who Should Not Take Ropinirole?

Absolute contraindication is hypersensitivity to ropinirole or any excipients, including urticaria, angioedema or rash.

Exercise caution in patients with severe hepatic or renal impairment, a history of psychosis or cardiovascular disease, and in those with prior impulse‑control disorders.

Adverse Effects

What Side Effects Should Patients Expect?

Common effects include nausea, vomiting, dizziness, somnolence, headache, constipation, insomnia, peripheral oedema, visual disturbances and sweating.

Serious risks include hallucinations, sudden sleep episodes and the emergence of compulsive behaviours such as pathological gambling or binge eating.

Baseline psychiatric screening and caregiver counselling on behavioural changes and daytime sleep attacks are advised.

Monitor orthostatic vitals during titration and reduce dose or switch agents if intolerable effects occur.

Interaction Mapping

Food Interactions

Does Food Affect Ropinirole Absorption?

Absorption is not heavily food‑dependent, but taking tablets with food may reduce nausea in some patients.

No injectable or topical forms are commercially available — only IR and ER tablets in the strengths noted above.

Drug Combinations To Avoid

Which Medicines Need Careful Checking?

Avoid combinations that increase sedation such as benzodiazepines, opioids and some antipsychotics due to additive somnolence.

Caution with antihypertensives because orthostatic hypotension can be exacerbated.

Dopamine antagonists such as metoclopramide or certain antipsychotics may reduce clinical benefit.

Ropinirole is metabolised in the liver and exposure may be altered by strong CYP1A2 inhibitors or inducers, so monitor and adjust dosing as required.

Patient Experience Analysis

Survey Data

What Do Patients Report In Clinics?

Registry and clinic surveys in the UK and EU show high patient‑reported benefit for motor control in Parkinson’s and marked symptom reduction in RLS at low doses.

Patients value symptom relief, tolerability and simplified dosing when switched to extended‑release formulations.

Early nausea and daytime sleepiness are the most commonly reported complaints.

Forum Trends

What Are Patients Saying Online?

Patient communities recommend slow titration and report switching to Requip XL or generic ER forms for better adherence and fewer peak‑side effects.

Forums raise questions about brand versus generic products, price and availability, and emphasise the need for clear counselling on impulse control and driving safety.

Caregiver monitoring for behavioural changes is frequently suggested as a practical safety step.

Distribution And Pricing Landscape

How Widely Available Is Requip In The UK Market?

Requip and Requip XL are available in the UK and EU and multiple generics are supplied by manufacturers such as Teva, Mylan and Sandoz.

Pack presentations commonly include blister packs or bottles of 21, 28, 30 or 100 tablets depending on supplier and local norms.

Generics drive down NHS acquisition costs and procurement choices determine which brands are dispensed under local formularies.

Extended‑release tablets (Requip XL and branded generics) generally cost more than immediate‑release generics and tendering influences local availability.

In our online pharmacy, requip is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Table

• Pramipexole: Similar efficacy as a non‑ergot dopamine agonist; different side‑effect profile with relatively higher D3 activity.
• Rotigotine (Neupro patch): Offers transdermal delivery and continuous dopaminergic stimulation; useful where oral intake is difficult.
• Bromocriptine and Cabergoline: Older ergoline agents used less frequently due to side‑effect profiles.
• Levodopa/Carbidopa: Gold standard for motor control in advanced Parkinson’s but associated with long‑term motor complications.

Pros And Cons

Why Choose Ropinirole Over Others?

Pros: multiple dosage strengths, an ER option for once‑daily dosing, established efficacy for both Parkinson’s disease and RLS and wide generic availability.

Cons: risk of impulse control disorders, somnolence and the need for slow titration; hepatic metabolism complicates dosing in liver disease.

Rotigotine avoids oral GI effects but may cause skin reactions, while levodopa offers superior motor control at the cost of later motor complications.

Regulatory Status

Who Has Approved Ropinirole?

Ropinirole is approved by major regulators for Parkinson’s disease and RLS and is a prescription‑only medicine globally.

The US FDA originally approved branded ropinirole in 1997 and branded Requip has been discontinued in the US though generics remain available.

The EMA covers approvals in EU markets and multiple generics and branded generics are authorised in European member states.

Registration and product licences vary by country so prescribers should consult national regulatory databases and product SPCs for details.

Consolidated FAQ

Which Strengths Are Available?

Immediate‑release tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg.

Extended‑release tablets: 2 mg, 4 mg, 6 mg, 8 mg and 12 mg.

Is Requip Available In The UK?

Yes. Requip and multiple generics are available in the UK and EU.

How Fast Does It Work?

Symptom improvement may be noticed over days to weeks depending on indication and titration speed.

Major Side Effects?

Nausea, dizziness, somnolence, orthostatic hypotension, hallucinations and impulse control disorders are the principal concerns.

Can I Drive?

Do not drive if sedated or experiencing sudden sleep attacks and inform the DVLA or follow local driving guidance where applicable.

Can I Switch Between Brands?

Yes; generics are common, but observe patients closely when switching in vulnerable individuals.

Storage?

Store at 20–25°C, protect from light and moisture and keep out of reach of children.

Visual Guide

What Should A Clinician Or Patient See At A Glance?

Include product forms: IR tablets 0.25–5 mg and ER tablets 2–12 mg with packaging notes for blister packs or bottles in 21–100 tablet presentations.

Titration ladder for Parkinson’s: 0.25 mg TID then weekly increases according to response up to 24 mg total daily dose.

RLS bedtime dosing: 0.25 mg once nightly 1–3 hours before bed increasing up to about 4 mg where needed.

Safety icons: no driving if drowsy, watch for compulsive behaviours, take orthostatic precautions when standing from sitting.

Flowchart: Start → Monitor Weekly During Titration → Assess Adverse Effects → Consider ER (Requip XL or generic ER) For Adherence Issues.

Add MHRA/emc reference icons and space for local formulary details when used in UK outpatient leaflets.

Storage And Transport

What Are The Practical Storage Rules?

Store at 20–25°C with permitted excursions between 15–30°C.

Keep in the original, tightly closed container and protect from light and moisture.

Typical pack sizes are 21, 28, 30 or 100 tablets depending on market norms.

Transport under normal ambient conditions within the recommended excursion range and avoid prolonged exposure to excessive heat or humidity.

Pharmacies should maintain stock rotation and store IR and ER products separately to prevent dispensing errors.

Dispose of out‑of‑date or compromised stock according to NHS and MHRA guidance.

Guidelines For Proper Use

What Should UK Prescribers Document And Monitor?

Confirm the diagnosis of Parkinson’s disease or RLS and review contraindications before starting therapy.

Document baseline psychiatric history and driving status and counsel patients and carers on risk of impulse control disorders and daytime sleep attacks.

Prescribe starting doses consistent with standard practice: PD start 0.25 mg TID with slow weekly titration; RLS start 0.25 mg nightly 1–3 hours before bed.

Choose ER formulations (Requip XL or generic ER 2–12 mg) for once‑daily dosing when adherence or peak‑related side effects are a concern.

Review patients within 1–4 weeks of initiation and then periodically for somnolence, orthostatic hypotension and behavioural changes.

Provide written information: missed‑dose rules (do not double), overdose signs and storage instructions, and record counselling and follow‑up plans in the clinical record.

Delivery Across United Kingdom